TTM
38.0%
YoY change
+4.45pp
Trough year (2002)
-20.0%
Peak year (2025)
37.2%
Latest annual
37.2%
EBITDA Margin history chart for ResMed (RMD) from 1993 to 2025
Latest: 37.2%
EBITDA Margin change chart for ResMed (RMD) from 1993 to 2025
Latest: +4.45pp
EBITDA Margin history table for ResMed (RMD) from 1993 to 2025
| 2025 | 37.2% | +4.45pp | ||
| 2024 | 32.7% | +0.55pp | ||
| 2023 | 32.2% | -0.71pp | ||
| 2022 | 32.9% | -1.65pp | ||
| 2021 | 34.5% | +1.04pp | ||
| 2020 | 33.5% | +6.42pp | ||
| 2019 | 27.1% | -1.99pp | ||
| 2018 | 29.1% | +1.54pp | ||
| 2017 | 27.5% | -0.90pp | ||
| 2016 | 28.4% | -0.30pp | ||
| 2015 | 28.7% | -2.46pp | ||
| 2014 | 31.2% | +0.16pp | ||
| 2013 | 31.0% | +0.14pp | ||
| 2012 | 30.9% | +0.77pp | ||
| 2011 | 30.1% | +0.62pp | ||
| 2010 | 29.5% | +8.82pp | ||
| 2009 | 20.7% | -3.85pp | ||
| 2008 | 24.5% | +11.93pp | ||
| 2007 | 12.6% | -16.09pp | ||
| 2006 | 28.7% | -3.50pp | ||
| 2005 | 32.2% | +7.02pp | ||
| 2004 | 25.2% | -4.02pp | ||
| 2003 | 29.2% | +49.19pp | ||
| 2002 | -20.0% | -53.63pp | ||
| 2001 | 33.6% | -0.45pp | ||
| 2000 | 34.1% | +0.32pp | ||
| 1999 | 33.7% | +2.17pp | ||
| 1998 | 31.6% | +9.42pp | ||
| 1997 | 22.2% | +7.99pp | ||
| 1996 | 14.2% | -0.31pp | ||
| 1995 | 14.5% | +2.96pp | ||
| 1994 | 11.5% | -0.18pp | ||
| 1993 | 11.7% | — |
- 202537.2%+4.45pp
- 202432.7%+0.55pp
- 202332.2%-0.71pp
- 202232.9%-1.65pp
- 202134.5%+1.04pp
- 202033.5%+6.42pp
- 201927.1%-1.99pp
- 201829.1%+1.54pp
- 201727.5%-0.90pp
- 201628.4%-0.30pp
- 201528.7%-2.46pp
- 201431.2%+0.16pp
- 201331.0%+0.14pp
- 201230.9%+0.77pp
- 201130.1%+0.62pp
- 201029.5%+8.82pp
- 200920.7%-3.85pp
- 200824.5%+11.93pp
- 200712.6%-16.09pp
- 200628.7%-3.50pp
- 200532.2%+7.02pp
- 200425.2%-4.02pp
- 200329.2%+49.19pp
- 2002-20.0%-53.63pp
- 200133.6%-0.45pp
- 200034.1%+0.32pp
- 199933.7%+2.17pp
- 199831.6%+9.42pp
- 199722.2%+7.99pp
- 199614.2%-0.31pp
- 199514.5%+2.96pp
- 199411.5%-0.18pp
- 199311.7%—
EBITDA Margin values are taken from ResMed's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA Margin at ResMed (RMD)
According to ResMed's latest reported financial statements, the company's latest reported EBITDA margin is 38.0%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual EBITDA margin for ResMed (RMD) came in at 37.18% – expanded 4.4 percentage points year-over-year.
The record annual EBITDA margin stands at 37.18%, reached in 2025; the historical low of -20.01% was recorded in 2002.
ResMed EBITDA Margin by Year
ResMed EBITDA Margin 2025: 37.2%
2025's EBITDA margin for ResMed came in at 37.18%, expanded 4.4 percentage points from 2024. This figure represents the highest annual value in the available history.
ResMed EBITDA Margin 2024: 32.7%
ResMed posted EBITDA margin of 32.73% in 2024, expanded 0.6 percentage points from 2023.
ResMed EBITDA Margin 2023: 32.2%
In 2023, ResMed reported EBITDA margin of 32.18%, contracted 0.7 percentage points from 2022.
ResMed EBITDA Margin 2022: 32.9%
ResMed EBITDA margin in 2022 was 32.88%, contracted 1.6 percentage points from 2021.
ResMed EBITDA Margin 2021: 34.5%
ResMed EBITDA margin in 2021 was 34.53%.
See more financial history for ResMed (RMD).
Sector peers by EBITDA Margin
Healthcare peers of ResMed (RMD), ranked by their latest EBITDA margin
| 55.4% | |
| 46.6% | |
| 45.9% | |
| 34.6% | |
| 33.9% | |
| 30.3% | |
| 26.9% | |
| 5.1% |
- 55.4%
- 46.6%
- 45.9%
- 34.6%
- 33.9%
- 26.9%
Frequently asked questions
ResMed (RMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation